Immune checkpoint blockades for ovarian can-cer:current status and challenges
CHEN Yu-lian
ZANG Rong-yu
Abstract：Immune checkpoint blockades(ICBs)have achieved breakthrough in the treatment of multiple solid tumors.However,in the treatment of ovarian cancer,mainly high grade serous tubo-ovarian cancer(HGSC),neither single agent of ICBs nor ICB-based combination therapies have shown good results in clinical researches.The tumor immune microenviron-ment of ovarian cancer is highly complex and heter-ogenous,with low PD-L1 expression,low tumor mutation burden,different phenotypes of lymphocytes infiltration in tumors,and presence of multiple im-munosuppressive cells.We still need well-designed clinical trials considering the patients'genomic and immune phenotypes to improve the accuracy and ef-fectiveness of treatment.
Keywords：ovarian cancerimmune checkpoint blockadetumor immune microenvironment
Publication Date：2024-11-02
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 1078-1082 )